Giulia Barletta

1.1k total citations
44 papers, 702 citations indexed

About

Giulia Barletta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Giulia Barletta has authored 44 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Giulia Barletta's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (9 papers). Giulia Barletta is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (9 papers). Giulia Barletta collaborates with scholars based in Italy, United States and United Kingdom. Giulia Barletta's co-authors include Carlo Genova, Francesco Grossi, Erika Rijavec, Maria Giovanna Dal Bello, Federica Biello, Angela Alama, Simona Coco, Anna Truini, Irene Vanni and Claudio Sini and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Molecular Cancer.

In The Last Decade

Giulia Barletta

43 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giulia Barletta Italy	18	408	301	228	202	101	44	702
Angel Qin United States	12	343 0.8×	201 0.7×	178 0.8×	122 0.6×	94 0.9×	33	561
Federica Biello Italy	20	634 1.6×	418 1.4×	267 1.2×	292 1.4×	154 1.5×	56	994
Jillian Wilhelmina Paulina Bracht Spain	14	283 0.7×	270 0.9×	381 1.7×	207 1.0×	63 0.6×	29	639
Keyi Jia China	13	441 1.1×	196 0.7×	276 1.2×	111 0.5×	234 2.3×	27	730
Fernando C. Santini United States	13	685 1.7×	464 1.5×	211 0.9×	143 0.7×	115 1.1×	34	958
Giuliana Restante Italy	13	322 0.8×	328 1.1×	340 1.5×	297 1.5×	89 0.9×	25	721
Andrea Ravelli Italy	10	288 0.7×	251 0.8×	200 0.9×	106 0.5×	53 0.5×	15	543
R. Molife United Kingdom	11	291 0.7×	277 0.9×	300 1.3×	162 0.8×	54 0.5×	24	694
Caicun Zhou China	12	435 1.1×	393 1.3×	197 0.9×	106 0.5×	82 0.8×	36	710
Giuseppina Rosaria Rita Ricciardi Italy	16	588 1.4×	483 1.6×	313 1.4×	293 1.5×	55 0.5×	42	947

Countries citing papers authored by Giulia Barletta

Since Specialization

Citations

This map shows the geographic impact of Giulia Barletta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Barletta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Barletta more than expected).

Fields of papers citing papers by Giulia Barletta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Barletta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Barletta. The network helps show where Giulia Barletta may publish in the future.

Co-authorship network of co-authors of Giulia Barletta

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Barletta. A scholar is included among the top collaborators of Giulia Barletta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Barletta. Giulia Barletta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nardin, Simone, Giovanni Rossi, Giulia Barletta, et al.. (2025). Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives. Cancers. 17(4). 652–652. 3 indexed citations

Zullo, Lodovica, Filippo Gustavo Dall’Olio, Giovanni Rossi, et al.. (2023). Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity. International Journal of Molecular Sciences. 25(1). 224–224. 3 indexed citations

Zullo, Lodovica, Giovanni Rossi, Simona Coco, et al.. (2022). Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. Expert Opinion on Biological Therapy. 22(10). 1259–1273. 17 indexed citations

Carrega, Paolo, Lodovica Zullo, Chiara Dellepiane, et al.. (2022). Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. Cancers. 14(20). 5046–5046. 14 indexed citations

Coco, Simona, Simona Boccardo, Marco Mora, et al.. (2020). Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. Clinical Breast Cancer. 21(3). 218–230.e6. 2 indexed citations

Genova, Carlo, Simona Boccardo, Marco Mora, et al.. (2019). Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine. 8(10). 1566–1566. 23 indexed citations

Coco, Simona, Silvia Bonfiglio, Davide Cittaro, et al.. (2019). Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers. 11(4). 441–441. 3 indexed citations

Coco, Simona, Angela Alama, Irene Vanni, et al.. (2017). Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences. 18(5). 1035–1035. 37 indexed citations

Genova, Carlo, Paolo Carrega, Gabriella Pietra, et al.. (2017). P3.02c-072 Predictive Immunologic Markers of Response to Nivolumab in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1320–S1321. 1 indexed citations

10.

Grossi, Francesco, Erika Rijavec, Federica Biello, et al.. (2017). P3.02c-074 Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1322–S1322. 7 indexed citations

11.

Grossi, Francesco, Carlo Genova, Erika Rijavec, et al.. (2017). Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 117. 64–69. 12 indexed citations

12.

Bello, Maria Giovanna Dal, Rosangela Filiberti, Carlo Genova, et al.. (2017). P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 12(1). S827–S828. 3 indexed citations

13.

Biello, Federica, Giovanni Burrafato, Erika Rijavec, et al.. (2016). Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry. 16(9). 1142–1154. 8 indexed citations

14.

Vanni, Irene, Simona Coco, Anna Truini, et al.. (2015). Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform. International Journal of Molecular Sciences. 16(12). 28765–28782. 33 indexed citations

15.

Genova, Carlo, Erika Rijavec, Giulia Barletta, et al.. (2014). Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy. 15(6). 889–903. 20 indexed citations

16.

Coco, Simona, Anna Truini, Angela Alama, et al.. (2014). Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targeted Oncology. 10(3). 393–404. 35 indexed citations

17.

Coco, Simona, Anna Truini, Irene Vanni, et al.. (2014). Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. Current Drug Targets. 16(1). 47–59. 38 indexed citations

18.

Genova, Carlo, Erika Rijavec, Anna Truini, et al.. (2013). Pemetrexed for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 14(11). 1545–1558. 24 indexed citations

19.

Grossi, Francesco, Carlo Genova, Maria Giovanna Dal Bello, et al.. (2013). Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. Lung Cancer. 81(2). 236–240. 20 indexed citations

20.

Grossi, Francesco, Claudio Sini, Giulia Barletta, et al.. (2012). The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line.. Journal of Clinical Oncology. 30(15_suppl). 7577–7577. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact